FibroGen CMO Mark Eisner resigns; search underway for replacement

KYNTRA BIO, INC.

CMO Mark Eisner resigns effective Sept 8, 2023; departure voluntary with no disagreement.
Eisner to serve as consultant through Oct 11, 2023 at $15K/month; equity awards continue vesting.
Company has initiated search for a new Chief Medical Officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Eisner

Chief Medical Officer

KYNB · KYNTRA BIO, INC.

Effective: 2023-09-08
Filed: September 6, 2023, 7:59 PM ET

On August 31, 2023, Mark Eisner, M.D. resigned from his position as Chief Medical Officer of FibroGen, Inc. (the "Company"), effective September 8, 2023, to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Eisner resigned as Chief Medical Officer at KYNTRA BIO, INC..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On August 31, 2023, Mark Eisner, M.D. resigned from his position as Chief Medical Officer of FibroGen, Inc. (the "Company"), effective September 8, 2023, to pursue other opportunities.

View on SEC.gov

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-046574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.